Stock Market News for October 16, 2026

At a glance

On October 16, 2026, The Travelers Companies reported third-quarter net income of $1.917 billion; Citizens Financial Group reported Q3 net income of $636 million and raised its quarterly dividend to $0.52 per share; International Seaways agreed to acquire Bruton in transactions valuing the tanker company at approximately $370 million; ImmunityBio reported long-term data showing 84% cystectomy avoidance at three years with ANKTIVA plus BCG.

Earnings and results

The Travelers Companies (TRV) reported third-quarter 2026 net income of $1.917 billion, diluted earnings of $9.04 and core earnings of $9.18 per diluted share, with a combined ratio of 86.8% and quarterly net written premiums of $11.480 billion.

Citizens Financial Group (CFG) reported third-quarter 2026 net income of $636 million and EPS of $1.41, and the board raised the quarterly common stock dividend to $0.52 per share payable November 13, 2026.

Fox Factory Holding (FOXF) appointed Douglas Grimm interim CEO effective October 16, 2026, and provided preliminary third-quarter sales of $336 million–$340 million and adjusted EBITDA of $38 million–$42 million.

Deals and combinations

International Seaways (INSW) agreed to acquire Bruton Limited in transactions valuing the tanker company at approximately $370 million, covering an initial ~50.5% stake at 0.0519 INSW shares per Bruton share with settlement expected on or about October 20, 2026.

Archimedes Tech SPAC Partners II (ATII) announced shareholder approval of the proposed business combination with Forge Nano, Inc., and expects the transaction to close in the coming days, with the combined company to trade on Nasdaq under NANO and NANOW upon closing.

XCF Global (SAFX) completed its all-stock business combination with Southern Energy Renewables and DevvStream, making both companies wholly owned subsidiaries and leaving XCF as the publicly traded parent with former Southern and DevvStream holders owning ~20.0% and ~10.43% of XCF common stock, respectively.

Drug trials and approvals

ImmunityBio (IBRX) reported long-term Phase 2/3 results showing a 71% complete response rate with ANKTIVA plus BCG in BCG-unresponsive NMIBC with CIS and that among responders cystectomy-free survival was 84% at 36 months, with responses extending beyond 53 months.

Fractyl Health (GUTS) reported its Revita device met the six-month co-primary endpoint in the REMAIN-1 pivotal study, with Revita participants retaining ~80% of GLP-1–induced weight loss versus 67% with sham and adjusted mean weight regain of 5.1% vs. 8.2% (p=0.0023).

Opus Genetics (IRD) received FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia, expanding RYZUMVI's U.S. indication and triggering a milestone payment to Opus under its licensing agreement with Viatris' affiliate.

Financings and offerings

Alector (ALEC) priced an underwritten common-stock offering expected to raise $75,030,000 by selling 36,600,000 shares at $2.05 per share, with closing expected on or about October 19, 2026.

Rubico (RUBI) signed a registered direct offering for an initial $8.5 million of senior convertible notes and warrants, issuing $9,444,444 of notes with a 10% original issue discount and a fixed conversion price of $0.3646 for the first tranche.

Curis (CRIS) entered into a private placement expected to raise approximately $8.5 million, covering 16,666,680 common shares or pre-funded warrants plus common warrants, at an effective combined price of $0.51 per share or pre-funded warrant with accompanying warrant.

Gauzy (GAUZ) closed a $7 million private placement on October 15, 2026, selling 2,383,279 ordinary shares at $2.9371 each to finance its court-approved debt settlement.

Share actions and restructurings

Robo.ai (AIIO) announced a proposed 1-for-25 reverse stock split of both ordinary share classes to take effect November 6, 2026, subject to shareholder approval at an October 26, 2026 extraordinary general meeting, with Class A shares moving from 13,817,501 to 552,701 and Class B from 222,116,290 to 8,884,684 if approved.

Moleculin Biotech (MBRX) announced a 1-for-20 reverse stock split effective October 20, 2026 at 12:01 a.m. Eastern Time, which will reduce outstanding common shares to approximately 1.05 million from about 20.9 million.

BUUU Group (BUUU) approved a 10-for-1 forward share split, with split-adjusted trading expected to begin October 26, 2026, subject to Nasdaq processing and leaving shareholder percentages unchanged.

Leadership changes

Ironwood Pharmaceuticals (IRWD) appointed Tammi Gaskins chief executive officer and a board member effective January 1, 2027; she will succeed Tom McCourt, who will retire from the CEO role and remain on the board.

Other notable news

NANO-X IMAGING (NNOX) provided preliminary third-quarter 2026 financial data and warned funding constraints raise substantial doubt about continuing operations, estimating cash, cash equivalents and deposits of approximately $26.0 million at September 30, 2026 versus $60.0 million at December 31, 2025.

Power Integrations (POWI) granted inducement equity awards on October 15, 2026 to 12 employees including 25,325 restricted stock units and 1,339 performance stock units, with RSU vesting over four years and PSU vesting tied to 2026 performance metrics.